Study #2022-0055
A Phase Ib Open-Label, Multicenter Study Evaluating the Safety, Efficacy, And Pharmacokinetics of Mosunetuzumab In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Mosunetuzumab, Tocilizumab, Venetoclax
Description
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed by the treating physician to continue their BTKi throughout the screening period and for the first two cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Lymphocytic Leukemia
Study phase:
Phase I
Physician name:
William Wierda
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.